All In Biotech

Drug Trial Radar · NCT05127954

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)

Last checked: Nov 19, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

1,200

Planned (sponsor's estimate)

Start

Jan 14, 2022

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate long term safety and tolerability of ubrogepant in the acute treatment of migraine in pediatric participants. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Pediatric participants (aged 6-17 years) with a history of migraine will be enrolled. Participants who completed the lead-in Study 3110-305-002, as well as those who were placebo responders and screen failed, will be eligible to enroll into this study. Around 1200 participants will be enrolled in the study at approximately 120 sites in the United States. Participants may receive ubrogepant oral tables to treat up to 8 migraine attacks of any intensity per month. There will be an option to take a second dose of study intervention (identical to initial dose), or rescue medication, starting 2 hours after the initial dose. The study duration will be up to 54 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The safety and tolerability of the treatment will be checked by medical assessments, blood tests, checking for adverse events and completing questionnaires.

Conditions

  • Migraine

Interventions

  • UbrogepantDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Adverse Events (AEs)Time frame: up to 54 weeks
  2. Percentage of Participants with Potentially Clinically Significant Clinical 12-lead Electrocardiogram (ECG)Time frame: Up to 54 Weeks
  3. Percentage of Participants with Potentially Clinically Significant Vital Sign ParametersTime frame: Up to 54 Weeks
  4. Percentage of Participants with Potentially Clinically Significant lab valuesTime frame: Up to 54 Weeks
  5. Percentage of with Participants with Suicidal Ideation or Suicidal BehaviorTime frame: Up to 54 Weeks
  6. Percentage of Participants with Change in Menstrual CycleTime frame: Up to 54 Weeks
  7. Change from baseline in Tanner staging scoreTime frame: Up to 54 Weeks
  8. Change From baseline in Behavior Rating Inventory of Executive Function (BRIEF 2) questionnaireTime frame: up to 54 weeks

Locations

113 sites in 2 countries. Site status is shown where the registry gives one.

  • Rehabilitation & Neurological Services /ID# 240054

    Huntsville, Alabama

  • The Center for Clinical Trials - Saraland /ID# 239448

    Saraland, Alabama

  • Preferred Research Partners /ID# 238979

    Little Rock, Arkansas

  • Advanced Research Center /ID# 238967

    Anaheim, California

  • Neuro Pain Medical Center /ID# 239135

    Fresno, California

  • Alliance for Research Alliance for Wellness /ID# 233497

    Long Beach, California

  • Children's Hospital Los Angeles /ID# 239446

    Los Angeles, California

  • Excell Research, Inc /ID# 233495

    Oceanside, California

  • Paradigm Clinical Research - San Diego /ID# 269611

    San Diego, California

  • Lumos Clinical Research Center /ID# 239018

    San Jose, California

  • Pacific Clinical Research Management Group /ID# 238503

    Upland, California

  • Sunwise Clinical Research /ID# 238458

    Walnut Creek, California

  • Children's Hospital Colorado - Aurora /ID# 239838

    Aurora, Colorado

  • IMMUNOe Research Centers /ID# 240846

    Centennial, Colorado

  • MCB Clinical Research Centers /ID# 240999

    Colorado Springs, Colorado

  • New England Institute for Clinical Research /ID# 239019

    Stamford, Connecticut

  • Emerson Clinical Research Inst /ID# 238455

    Washington D.C., District of Columbia

  • Encore Medical Research of Boynton Beach LLC /ID# 248720

    Boynton Beach, Florida

  • Gulf Coast Clinical Research Center /ID# 233335

    Fort Myers, Florida

  • Sarkis Clinical Trials /ID# 233493

    Gainesville, Florida

  • Northwest Florida Clinical Research Group, LLC /ID# 244396

    Gulf Breeze, Florida

  • A.G.A Clinical Trials /ID# 238409

    Hialeah, Florida

  • Encore Medical Research /ID# 247463

    Hollywood, Florida

  • Advanced Research Institute of Miami /ID# 240712

    Homestead, Florida

  • Auzmer Research /ID# 241514

    Lakeland, Florida

  • Columbus Clinical Services, Llc /Id# 238968

    Miami, Florida

  • My Preferred Research LLC /ID# 239020

    Miami, Florida

  • Neurology & Pain Medicine /ID# 241860

    Miami, Florida

  • Medical Research Group of Central Florida /ID# 240711

    Orange City, Florida

  • Clinical Associates of Orlando, LLC /ID# 272623

    Orlando, Florida

  • Suncoast Clinical Research - Palm Harbor /ID# 233535

    Palm Harbor, Florida

  • Asclepes Research Centers - Spring Hill /ID# 231872

    Spring Hill, Florida

  • University of South Florida- Neuroscience Institute /ID# 233420

    Tampa, Florida

  • Encore Medical Research - Weston /ID# 248335

    Weston, Florida

  • Pediatric Neurology and Epilepsy Specialists /ID# 233336

    Winter Park, Florida

  • Global Research Associates /ID# 243504

    Atlanta, Georgia

  • Rare Disease Research, LLC /ID# 238833

    Atlanta, Georgia

  • Clinical Integrative Research Center of Atlanta (CIRCA) /ID# 238852

    Atlanta, Georgia

  • Coastal Georgia Child Neurology /ID# 240845

    Brunswick, Georgia

  • CenExcel iResearch LLC /ID# 239832

    Decatur, Georgia

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.